# Rectify Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rectify-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.rectifypharma.com
- Total disclosed funding: $96M
- Latest round: Series A (Oct 14, 2021)
- Investors on record: 4

## About

Founded in 2020 by Jonathan Moore and based in Massachusetts, US, Rectify Pharmaceuticals, Inc. operates as a biotechnology company that develops positive functional modulators (PFMs) for patients with serious genetic diseases. In October 2021, Rectify Pharmaceuticals, Inc. raised USD 100 million in series A funding co-led by new investors Atlas Venture, Omega Funds, Forbion, and Longwood Fund.

The company develops Positive Functional Modulators (PFMs) which are disease-modifying therapeutics that restore ABC transporter function. ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system. 

Rectify plans to use the latest financing to fund the company through its first human proof-of-concept (POC) studies.

## Funding rounds

- Series A, Oct 14, 2021, $96M — Atlas Venture, Forbion, Omega Funds, Longwood Fund

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A